Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer
In Partnership With:
Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).
Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).
The decision whether to treat a patient with either abiraterone or enzalutamide as initial treatment usually depends on the patient profile. Abiraterone requires low-dose prednisone, while enzalutamide has potential CNS toxicities, which allows clinicians to choose the most appropriate treatment based on each individual patient.
